CureVac Says Phase 1 Clinical Trial of CV8102 Shows Immune Response in Oncology

• (PLX AI) - CureVac says Promising Data at SITC from Phase 1 Study of Oncology Candidate CV8102 Showing Systemic Immune Response.
• • Immune profiling of clinical trial participants in Phase 1 dose-escalation study shows immune response in both injected and non-injected lesions
• • CureVac Expansion part of Phase 1 study fully recruited; results expected in the second half of 2022
• • The data support the hypothesis that local injection of the RNA immuno-modulator into a single tumor lesion is able to induce a systemic response leading to immune attack against both injected and non-injected tumors, the company said